key: cord-0909473-fwxgzn8s
authors: Vilaro, Juan; Al-Ani, Mohammad; Manjarres, Diana Gomez; Lascano, Jorge E.; Cherabuddi, Kartik; Elgendy, Akram Y.; Bleiweiss, Mark S.; Parker, Alex M.; Ahmed, Mustafa M.; Aranda, Juan M.
title: Severe COVID-19 After Recent Heart Transplantation Complicated by Allograft Dysfunction
date: 2020-06-08
journal: JACC Case Rep
DOI: 10.1016/j.jaccas.2020.05.066
sha: 0d31819bb1bd451573ad957bf3751a358c90ddbd
doc_id: 909473
cord_uid: fwxgzn8s

Abstract A 50-year-old male presented with atrial flutter 25 days after heart and kidney transplantation. Rejection was excluded, however, he developed severe COVID-19 with cardiac allograft dysfunction. Despite continued corticosteroids and tacrolimus, he remained aviremic. Respiratory and myocardial function recovered after a week of mechanical ventilation. The cardiomyopathy was stress induced.

A 50-year-old African American male presented 25 days after combined heart and kidney transplant with asymptomatic atrial flutter. He converted spontaneously to sinus rhythm. BP was 128/75, HR 95 BPM, temperature 36.8 C. Cardiopulmonary examination was normal.

Endomyocardial biopsy was negative for rejection. Hemodynamics were normal and graft function was hyperdynamic.

The patient developed cough and rhinorrhea 48 hours later. Nasopharyngeal swab was positive for SARS-CoV-2. He had no dyspnea. Chest radiograph and pulse oximetry on room air were normal. Prednisone dose had just been reduced to 30 mg after the biopsy. Tacrolimus was continued and mycophenolate dose was reduced by 50%. Hydroxychloroquine was started. After 3 days of monitoring with no clinical change he was discharged to home isolation with pulse oximeter and plans for daily telemedicine assessments.

Three days later the patient presented to the emergency department with rapidly progressive respiratory distress and hypoxia.

The patient had history of end-stage non-ischemic cardiomyopathy, diabetes, and chronic kidney disease. He underwent implantation of left ventricular assist device (LVAD) as a bridge to cardiac transplantation, complicated by late onset post-LVAD right ventricular dysfunction with inotrope dependence and severe cardiorenal syndrome 2 years later. Due to recurrent hospitalizations for intractable hypervolemia that was deemed non-dischargeable, he was approved by the UNOS board as a status 2 criteria exemption for heart transplantation. He underwent heart transplantation on 2/28/2020, followed by renal transplant the following day, both without complications. Basiliximab was used to induce immunosuppression followed by maintenance with prednisone, tacrolimus, and mycophenolate mofetil.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), heart transplant rejection, viral myocarditis, stress cardiomyopathy.

Chest radiograph showed extensive bilateral airspace opacities.. Laboratories were significant for elevated ferritin at 648 ng/ml, CRP 74.9 mg/L, and d-dimer 4.81ug/ml, raising concern for Cytokine Release Syndrome. Electrocardiogram showed sinus rhythm with no STchanges. High sensitivity troponin was mildly elevated (34 pg/ml), with a flat trend. TTE demonstrated new biventricular systolic dysfunction with LVEF 40%, and moderately depressed right ventricular function. Serum SARS-CoV-2 PCR performed through a research pathway was negative.

He was admitted to intensive care where he required intubation and mechanical ventilation. His lowest PaO2/FiO2 ratio was 116. Lung protective ventilation along with deep sedation, paralytics, and inhaled epoprostenol were started for severe acute respiratory distress syndrome (ARDS). He was excluded from randomized treatment trials due to immunosuppression, but met institutional criteria for compassionate off-label use of Tocilizumab. One 400mg IV dose was administered after risk-benefit analysis and consent of patient's legal representative. He received azithromycin and broad-spectrum antibiotics for possible hospital-acquired pneumonia, and hydroxychloroquine was continued with daily QTc monitoring. Prednisone was switched to stress dose IV hydrocortisone. Tacrolimus was switched to continuous infusion with target steady state level of 10-12. Mycophenolate was discontinued.

Lung protective ventilation was utilized, and he required 12 hours of paralysis.

PaO2/FiO2 ratio remained above 150 without proning. Diuretics were given to maintain daily negative fluid balance, monitoring for hypotension or worsening renal function. He developed a mild acute kidney injury that resolved with no change in therapy. Mean arterial pressure and other end-organ functions remained normal throughout his course without vasopressors or inotropes. Respiratory failure improved gradually, and he was extubated on day 7, off oxygen therapy by day 12. A repeat TTE performed on day 8 showed normalization of biventricular function. He was discharged on hospital day 14.

Since the emergence of (SARS-CoV-2) from COVID-19 infection and declaration of the disease as a global pandemic, immunocompromised and solid organ transplant (SOT) recipients have been considered a vulnerable population with projected worse outcomes(1). Data on presentation, management and prognosis of COVID-19 in SOT recipients is scarce (2) (3) (4) . At the time our patient underwent transplant, no COVID-19 cases had been reported in our state. In this case we felt the risk benefit ratio of heart transplantation during the evolving pandemic favored proceeding with transplant due to the high mortality associated with his LVAD complications.

To our knowledge, this is the first reported case of severe COVID-19 infection diagnosed within 30 days of heart transplantation complicated by allograft dysfunction in the setting of a recent negative biopsy. The concomitant graft dysfunction presented a diagnostic and therapeutic dilemma. The differential included rejection, the most common cause in the first year post transplant, as well as non-rejection mechanisms, specifically viral myocarditis or stress cardiomyopathy, both of which have been described in COVID-19 (5, 6) . The approach to management would greatly vary depending on the leading consideration, as treatment for rejection may be contradictory to that of a severe viral infection. A biopsy done at the time of arrhythmia showed no rejection or myocarditis, and there were no detectable donor specific antibodies. Serum COVID PCR done 2 days after the abnormal echo was negative. We concluded that without any specific evidence for rejection or myocarditis, our patient most likely experienced transient stress injury to the allograft from critical illness that resolved as his condition improved.

Currently, there is not sufficient evidence supporting the use of interferons, gamma globulins , antivirals, steroids, hydroxychloroquine, or tocilizumab in critically ill patients(1).

Zhou et al. reported predictors of in-hospital mortality on a cohort 191 patients in Wuhan, China with confirmed COVID-19. The mortality rate in patients with respiratory failure was 98%, and a serum d-dimer greater than 1 ug/ml was an independent risk factor for in-hospital death(7).

Significant improvement in our patient's respiratory status was temporally related to treatment with tocilizumab and stress-dose steroids during the critical illness phase. However, we are unable to attribute patient's improvement to these specific measures as they occurred simultaneously with standard supportive care. However, despite being on high dose triple agent immunosuppression and presenting with major risk factors for in-hospital mortality, he survived with excellent recovery. This supports further investigation on early use of interleukin-6 inhibitors in high risk patients with severe COVID-19.

To date, there is still no reliable data to guide immunosuppression management for heart transplant patients with COVID-19. Complete withdrawal of immunosuppression during severe COVID-19 has been reported, but our patient's date of transplant was much more recent than the reported cases(3). We felt complete cessation of immunosuppression within one month of transplant posed prohibitively high rejection risk, hence mycophenolate was stopped but tacrolimus was continued. Clinical course timeline is summarized in Figure 1 .

The patient reports continued gradual recovery by weekly telemedicine assessments postdischarge. Mycophenolate has been resumed. COVID-19 PCR remains detectable by nasopharyngeal swab 36 days after the initial diagnosis. Repeat endomyocardial biopsy is planned once PCR becomes negative.

Our case shows that severe COVID-19 is a survivable illness despite intense immunosuppression regimens in patients who are early post heart transplant. We identify stress cardiomyopathy in the differential for allograft dysfunction complicating COVID-19 early postheart transplant, highlighting complete reversibility in the short term if patient recovers.

-To be able to make the differential diagnosis of acute cardiac dysfunction in the setting of severe COVID-19 early post heart transplantation -To understand the need for individualized management balancing risks of infection and rejection in heart transplant recipients with severe infections early post-transplant. 

Management of Critically Ill Adults With COVID-19

The Variety of Cardiovascular Presentations of COVID-19

First Cases of COVID-19 in Heart Transplantation From China. The J Heart Lung Transplant

Epidemiological And Clinical Characteristics Of Heart Transplant Recipients During The 2019 Coronavirus Outbreak In Wuhan, China: A Descriptive Survey Report

Typical takotsubo syndrome triggered by SARS-CoV-2 infection

Myocardial localization of coronavirus in COVID-19 cardiogenic shock

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study